Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

ClinicalTrials.gov ID: NCT00068432

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00068432. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of pancreatic cancer by stopping blood flow to the tumor and blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with celecoxib works in treating patients with metastatic pancreatic cancer.

Study identification

NCT ID
NCT00068432
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
28 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2003 (Type not available)
Primary completion
Jul 2005 (Actual)
Completion
Jul 2005 (Actual)
Last update posted
Oct 31, 2018

2003 – 2005

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center Fort Smith Arkansas 72913 —
M.D. Anderson Cancer Center - Orlando Orlando Florida 32806-2134 —
CCOP - Atlanta Regional Atlanta Georgia 30342-1701 —
CCOP - Carle Cancer Center Urbana Illinois 61801 —
CCOP - Wichita Wichita Kansas 67214-3882 —
CCOP - Kansas City Kansas City Missouri 64131 —
CCOP - Cancer Research for the Ozarks Springfield Missouri 65807 —
CCOP - Dayton Dayton Ohio 45429 —
CCOP - Columbia River Oncology Program Portland Oregon 97225 —
M.D. Anderson Cancer Center at University of Texas Houston Texas 77030-4009 —
All Saints Cancer Center at All Saints Healthcare Racine Wisconsin 53405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00068432, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2018 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.